Journal
MEDCHEMCOMM
Volume 8, Issue 1, Pages 53-66Publisher
ROYAL SOC CHEMISTRY
DOI: 10.1039/c6md00394j
Keywords
-
Funding
- Fundacao para a Ciencia e Tecnologia (FCT) [SFRH/BPD/100434/2014]
- Research Center Grant Centre for Biomedical Research [UID/BIM/04773/2013, 1334]
- Norwegian Research Council
- Norwegian Cancer Society and Helse Vest Health Authority
- ProRegem grant [PD/BD/114258/2016]
- Fundação para a Ciência e a Tecnologia [UID/BIM/04773/2013, SFRH/BPD/100434/2014] Funding Source: FCT
Ask authors/readers for more resources
Intrinsic and acquired resistance to conventional and targeted therapeutics is a fundamental reason for treatment failure in many cancer patients. Targeted approaches to overcome chemoresistance as well as resistance to targeted approaches require in depth understanding of the underlying molecular mechanisms. The anti-cancer activity of a drug can be limited by a broad variety of molecular events at different levels of drug action in a cell-autonomous and non-cell-autonomous manner. This review summarizes recent insights into the adaptive mechanisms used by tumours to resist therapy including cellular phenotypic plasticity, dynamic alterations of the tumour microenvironment, activation of redundant signal transduction pathways, modulation of drug target expression levels, and exploitation of pro-survival responses.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available